Cancers, Vol. 11, Pages 1612: Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
Cancers, Vol. 11, Pages 1612: Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
Cancers doi: 10.3390/cancers11101612
Authors:
Andrea Weiss
Morgan Le Roux-Bourdieu
Marloes Zoetemelk
George M. Ramzy
Magdalena Rausch
Daniela Harry
Marijana Miljkovic-Licina
Katayoun Falamaki
Bernard Wehrle-Haller
Patrick Meraldi
Patrycja Nowak-Sliwinska
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity. To address this, we performed a phenotypically-driven screen to identify optimal multidrug combinations acting with high efficacy and selectivity in clear cell renal cell carcinoma (ccRCC). The search was performed using the Therapeutically Guided Multidrug Optimization (TGMO) method in ccRCC cells (786-O) and nonmalignant renal cells and identified a synergistic low-dose four-drug combination (C2) with high efficacy and negligible toxicity. We discovered that C2 inhibits multipolar spindle pole clustering, a survival mechanism employed by cancer cells with spindle abnormalities. This phenotype was also observed in 786-O cells resistant to sunitinib, the first line ccRCC treatment, as well as in melanoma cells with distinct percentages of supernumerary centrosomes. We conclude that C2-treatment shows a high efficacy in cells prone to form multipolar spindles. Our data suggest a highly effective and selective C2 treatment strategy for malignant and ...
Source: Cancers - Category: Cancer & Oncology Authors: Andrea Weiss Morgan Le Roux-Bourdieu Marloes Zoetemelk George M. Ramzy Magdalena Rausch Daniela Harry Marijana Miljkovic-Licina Katayoun Falamaki Bernard Wehrle-Haller Patrick Meraldi Patrycja Nowak-Sliwinska Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Melanoma | Multidrug Resistance | Renal Cell Carcinoma | Skin Cancer | Toxicology